10-K: Lifecore Biomedical Reports Net Loss Amid Strategic Shift

Lifecore Biomedical, Inc. reported a significant net loss for fiscal year 2025, despite progress in strategic initiatives and capacity expansion.

Summary

• Lifecore Biomedical, Inc. (LFCR) reported a net loss of $38.7 million for the fiscal year ended May 25, 2025, a significant decline from a net income of $12.0 million in the prior fiscal year.
• Total revenues remained relatively flat at $128.9 million for FY2025, compared to $128.3 million in FY2024.
• CDMO (Contract Development and Manufacturing Organization) revenues decreased by 7% to $90.1 million, primarily due to the completion of a discrete development project, reduced volumes from a customer working down inventory, and a customer termination.
• HA (Hyaluronic Acid) manufacturing revenues increased by 23% to $38.8 million, driven by demand from the largest customer's supply chain initiatives.
• Gross profit decreased by 4% to $40.3 million, with the gross profit percentage declining from 32.6% to 31.3%.
• Operating loss widened to $17.2 million from $8.8 million in the prior year.
• The company is highly leveraged with approximately $176.0 million in total indebtedness as of May 25, 2025, including a $173.5 million Term Loan Credit Facility with Alcon.
• Interest expense, net, increased by 21% to $21.8 million, with non-cash interest expense of $18.5 million due to accumulating paid-in-kind interest and amortization of debt discount.
• Cash and cash equivalents stood at $8.3 million as of May 25, 2025.
• The company identified and continues to address material weaknesses in its internal control over financial reporting related to Information and Communication, Control Activities, and Monitoring.
• Multiple legal proceedings are ongoing, including an SEC subpoena, a shareholder class action complaint, and a dispute with 22NW, LP, a preferred stockholder.
• Monetary penalties of $5.034 million have accrued as of May 25, 2025, under a registration rights agreement due to past delinquent SEC filings, with interest continuing to accrue at 12% per annum on the penalty amount.
• The company completed a private placement of common stock in October 2024, raising $24.3 million, which resulted in an anti-dilution adjustment to the Series A Convertible Preferred Stock conversion price from $7.00 to approximately $6.53 per share.
• Stockholders approved the removal of the 19.99% Exchange Cap on the conversion of Series A Convertible Preferred Stock in April 2025, which could lead to significant dilution (7,000,626 shares convertible as of May 25, 2025).
• The Board approved a change in the company's fiscal year end from the last Sunday of May to December 31, effective August 1, 2025.

Sentiment

Score: 4

Explanation: The company faces significant financial headwinds, including a substantial net loss, high leverage, and ongoing legal and internal control issues. While strategic initiatives like capacity expansion and new management are positive, they are currently overshadowed by the financial performance and operational challenges. The outlook remains uncertain due to these factors.

Positives

• Doubled revenue-generating capacity to support up to approximately $300 million in annual revenue through the installation of a new fully automated high-speed, multi-purpose 5-head aseptic isolator filler in September 2024.
• Strengthened financial position by raising $24.3 million in a private placement of common stock in October 2024.
• Secured a three-year term extension of the existing asset-based lending revolving credit facility with BMO Harris Bank N.A. in November 2024.
• Generated $17 million from the sale of certain excess capital equipment in January 2025, with the $10 million note receivable paid in full in June 2025.
• Implemented operational cost reductions, including overhead costs and professional fees.
• Made key executive officer appointments, including a new CEO in May 2024 and a new CFO in September 2024, along with other senior leadership roles.
• Reached a cooperation agreement with 22NW, LP in June 2024, leading to Board appointments aimed at reinforcing alignment with stockholders.
• Regained compliance with Nasdaq listing requirements in August 2024 by completing required SEC filings and holding the 2023 annual meeting.
• Enhanced business development strategy, increased investment in sales and marketing, and expanded the business development team.
• FDA completed a general drug product good manufacturing practices (cGMP) inspection in March 2025 and closed it in May 2025 without further required action, demonstrating strong regulatory compliance.
• Stockholders approved the removal of the 19.99% Exchange Cap on the issuance of Common Stock underlying the Series A Convertible Preferred Stock in April 2025, facilitating potential future conversions.

Negatives

• Reported a net loss of $38.7 million for the fiscal year ended May 25, 2025, a significant deterioration from a net income of $12.0 million in the prior year.
• Accumulated deficit reached $205.2 million as of May 25, 2025, indicating a history of losses.
• Operating loss increased to $17.2 million from $8.8 million in the prior year.
• Gross profit decreased by $1.6 million, and the gross profit percentage declined from 32.6% to 31.3%.
• CDMO revenue declined by 7% due to the completion of a discrete development project, reduced volumes from a customer working down inventory, and a customer termination.
• Highly leveraged with approximately $176.0 million in total indebtedness, leading to significant interest expense.
• Interest expense is expected to nearly triple by the term loan maturity in May 2029 due to accumulating paid-in-kind interest and amortization of the debt discount.
• Identified material weaknesses in internal control over financial reporting, which have affected financial statement reliability and caused significant accounting, legal, and advisory costs.
• Incurred $5.034 million in monetary penalties and ongoing interest due to past delinquent SEC filings under a registration rights agreement.
• Increased Selling, General, and Administrative (SG&A) expenses by $3.6 million, primarily due to a $3.7 million increase in stock-based compensation and $11.6 million in legal expenses related to legacy matters, including an SEC subpoena, activist investor, and securities class action claim.
• Recorded a $6.4 million loss on the sale of certain excess equipment and $0.6 million related to abandoned capital projects.
• The Redeemable Convertible Preferred Stock holders have the right to demand redemption for an estimated $50.2 million (plus $4.5 million in registration rights penalties) on or after June 29, 2026, which could require substantial additional capital.

Risks

• Material weaknesses in internal control over financial reporting may continue to affect financial statement reliability and incur additional costs.
• High leverage and significant interest expense may negatively impact results and limit cash flow for business needs and operational flexibility.
• A history of losses and the potential need for additional capital, which may not be available in the required amount, at the necessary time, or on favorable terms.
• Inability to retain existing customers, attract new customers, and sell additional products and services could adversely affect revenue growth and profitability.
• Success as a stand-alone CDMO is subject to customer demand based on factors beyond the company's control, including the ability to fill expanded production capacity.
• Significant revenue concentration on a few large customers, including Alcon (who is also a primary lender), poses a risk if agreements are terminated or orders are delayed/canceled.
• Adverse impacts from the terms of refinancing transactions with Alcon and the concentrated relationship with Alcon as both a significant customer and lender.
• Increasing competition in the highly competitive and regulated contract development and manufacturing industry.
• Profitability is dependent on obtaining appropriate pricing for products and services and controlling or passing along cost increases to customers.
• Failure to provide quality and timely CDMO services due to the highly complex nature of operations could lead to increased costs, lost revenue, and damaged customer relationships.
• Customers' failure to receive or maintain regulatory approval for product candidates or products could negatively impact revenue and profitability.
• The business is highly regulated, and failure to comply with cGMP and other regulations could result in restrictions, recalls, or interruptions to supply.
• Loss or compromise of the proprietary HA bacterial cell bank assets could materially impact business operations, product quality, and competitive position.
• Development and manufacturing activities may expose the company to product liability claims, which may not be fully covered by insurance or indemnification.
• Concentration of facilities in Chaska, Minnesota, makes the company vulnerable to unforeseen events like power outages or natural disasters.
• Dependence on single-source suppliers and service providers may cause disruption in operations if any supplier fails to deliver materials.
• Changes to U.S. trade policy, tariffs, and import/export regulations may have a material adverse effect on the business.
• The need to consider new business acquisitions to achieve growth strategy involves substantial effort, costs, and integration uncertainty.
• Future resales, or the perception of future resales, of common stock (including shares from preferred stock conversion) may cause the market price to drop significantly.
• The Redeemable Convertible Preferred Stock has preferential rights and significant influence over the company, potentially impacting common stockholders.
• Corporate organizational documents and Delaware law contain anti-takeover provisions that may inhibit or prohibit a takeover or management changes.
• The outcome of existing and future litigation and regulatory proceedings, and related fees, costs, and penalties, could have a material adverse effect on the business.
• Dependence on key employees; loss of senior leadership or qualified personnel could lead to difficulties in replacement and impact operating results.
• Reputation and business may be harmed if computer network security or databases containing trade secrets, proprietary information, or personal information are compromised.
• Challenges with the implementation of a new enterprise resource planning (ERP) system may impact business and operations.
• Third parties may claim that services or customer products infringe their intellectual property rights.
• Failure to protect customer and supplier intellectual property or the company's own intellectual property and proprietary processes could adversely affect future growth and success.

Future Outlook

The company believes it is well-positioned for future growth, supported by recent improvements and its strategic plan. It anticipates an ongoing need for additional capital to fund growth strategies, operations, and capital expenditures. Interest expense is projected to nearly triple by the Term Loan Credit Facility's maturity in May 2029. The company plans to change its fiscal year end to December 31, with a transition period report for May 26, 2025 to December 31, 2025, and will begin filing annual reports for calendar years starting December 31, 2026. A comprehensive ERP system implementation is targeted for the first quarter of calendar year 2026, expected to improve financial data reliability and internal controls. The company will also implement new tax law changes from 'The One, Big, Beautiful Bill Act' in its next quarterly report.

Management Comments

• We believe that we are well-positioned for future growth.
• The Company continues to believe that the claims are without merit and intends to vigorously defend against them.
• Management, with the oversight of the Audit Committee, is committed to remediating the identified control deficiencies.
• This decision to move its fiscal year-end, which had been based on the legacy businesses seasonality, will allow Lifecore to report in a timely manner with the majority of its peer companies, customers and other stakeholders, which the company believes is an important factor in evaluating operational and financial performance. It also aligns with the launch of the new ERP system and expected associated benefits.

Industry Context

Lifecore Biomedical operates in the intensely competitive and highly regulated contract development and manufacturing organization (CDMO) market. Its competition includes full-service contract manufacturers and large pharmaceutical companies that can insource manufacturing. The demand for Lifecore's services is significantly influenced by its customers' success in obtaining regulatory approvals and achieving commercial success for their products. Increasing consolidation within the pharmaceutical industry could also impact customer demand for outsourced services.

Comparison to Industry Standards

• The company highlights its strong multi-compendial quality and regulatory system and team, with an over 40-year track record with global regulatory bodies (FDA, EMA, ANVISA, etc.), positioning itself as a strong partner for companies seeking proven experience in QbD, cGMP compliance, and manufacturing excellence.
• The FDA completed a general drug product good manufacturing practices (cGMP) inspection in March 2025, which was closed in May 2025 without further required action, indicating compliance with regulatory standards, which is a key competitive advantage in the highly regulated CDMO industry.
• The company has established long-term relationships with global and emerging biopharmaceutical and biotechnology companies, with multiple customer relationships ranging from 20 to nearly 40 years, suggesting a strong retention rate compared to industry averages, though no specific benchmarks are provided.

Management Changes

Corporate Governance

Legal Proceedings

• SEC Subpoena: On February 16, 2024, the Chicago Regional Office of the SEC issued a subpoena seeking documents and information concerning the company's financial statement restatements. The company is cooperating.
• Shareholder Class Action Complaint: On July 29, 2024, a putative class action complaint was filed alleging false and misleading statements regarding financial results, internal controls, and financial prospects between October 7, 2020, and March 19, 2024. An amended complaint was filed on January 24, 2025, and the company filed a motion to dismiss on March 25, 2025.
• 22NW, LP Investor Dispute: On December 23, 2024, 22NW Fund, L.P. filed a complaint alleging material misrepresentations, breaches of a stock purchase agreement, and seeking registration delay fees and specific performance related to the Series A Redeemable Convertible Preferred Stock. The company filed a motion to dismiss most claims.
• Landlord Complaint: A complaint of unlawful detainer filed on January 12, 2024, by a landlord for a property leased by the divested Curation Foods business was settled on March 24, 2025.
• Yucatan Acquisition Compliance Matters: The DOJ declined to prosecute FCPA violations related to the formerly-held Yucatan subsidiary on November 16, 2023, after the company paid $407,000 in disgorgement. Related litigation with a former owner of Yucatan is ongoing, with a net award of $902,000 plus $275,000 in recoverable costs in the company's favor from a first trial, currently under appeal by both parties. A second trial is stayed, and a new complaint was filed by the plaintiff on June 30, 2025.

Related Party Transactions

• Alcon Research, LLC is a significant customer, accounting for 44% of revenues for the fiscal year ended May 25, 2025.
• Alcon is the primary lender under the Term Loan Credit Facility, with $173.5 million in borrowings outstanding as of May 25, 2025, bearing a fixed interest rate of 10% per annum, payable-in-kind until May 2026.
• The company entered into an equipment sale and leaseback transaction with Alcon in May 2023, resulting in a $7.73 million leaseback liability.
• Alcon provided cash advances totaling $307,000 as of May 25, 2025, to purchase and install Alcon-owned equipment on the company's premises.
• Alcon made a significant individual prepayment of $5.5 million in the fourth quarter of fiscal year 2024, accounted for as a contract liability.
• Interest expense incurred from Alcon borrowings was $18.879 million for the fiscal year ended May 25, 2025, including $18.473 million in non-cash interest expense.
• The company has guaranteed contractual minimum purchasing commitments to Alcon through 2031 and is required to maintain certain manufacturing capacity levels through 2033.

Stakeholder Impact

• Shareholders: Experienced a significant net loss, face potential dilution from preferred stock conversion, and are exposed to stock price volatility due to ongoing litigation and internal control issues. However, strategic improvements and capacity expansion offer potential long-term benefits.
• Employees: Subject to workforce optimization initiatives and a transformation of the finance and accounting department, leading to severance expenses. New executive leadership aims to strengthen the team and culture, with a focus on retention and development of technical staff.
• Customers: Benefit from expanded manufacturing capacity and enhanced business development efforts. The company's strong regulatory track record (e.g., FDA inspection closure without action) reinforces its position as a reliable CDMO partner. However, customer concentration poses a risk if key relationships are disrupted.
• Creditors (Alcon, BMO): The company's high leverage and ongoing financial performance challenges present risks. Compliance with debt covenants is critical, and the unique dual role of Alcon as both a major customer and primary lender creates a complex relationship dynamic.
• Regulatory Authorities: The company is actively addressing past compliance issues (SEC subpoena, Nasdaq listing) and maintaining current compliance (FDA inspection), indicating a commitment to regulatory adherence, though material weaknesses in internal controls remain a concern.

Next Steps

• File a Transition Report on Form 10-K/T for the period from May 26, 2025, to December 31, 2025.
• File annual reports for twelve-month periods ending December 31, beginning with the year ending December 31, 2026.
• File a Quarterly Report on Form 10-Q for the quarter ending September 30, 2025.
• Continue to implement the remediation plan for identified material weaknesses in internal control over financial reporting in fiscal year 2026.
• Undertake a comprehensive ERP system implementation, targeted for the first quarter of calendar year 2026.
• Test and monitor the design and operating effectiveness of internal controls over financial reporting following the ERP implementation.
• Establish and maintain ongoing evaluations to assess the effectiveness of internal controls over financial reporting.
• Implement tax law changes from 'The One, Big, Beautiful Bill Act' for the quarterly report ending September 30, 2025.
• Vigorously defend against the 22NW investor dispute and the shareholder class action complaint.
• Oppose the new complaint filed by the plaintiff in the Yucatan acquisition litigation, seeking its dismissal.
• Continue with the appeal process for the first trial related to the Yucatan acquisition litigation, following the company's notice of appeal on June 9, 2025, and the plaintiff's cross-appeal on July 1, 2025.

Key Dates

Recommendation

Lifecore Biomedical is in a transitional phase, having divested its food businesses to focus on its core CDMO operations. While the company has made commendable progress in strengthening its financial position, expanding manufacturing capacity, and improving corporate governance, the reported net loss, high leverage, and persistent material weaknesses in internal controls present significant financial and operational risks. The ongoing legal proceedings add further uncertainty. A 'Hold' recommendation is appropriate as the company navigates these challenges. Investors should monitor the effectiveness of remediation efforts, the resolution of legal matters, and the company's ability to translate its strategic initiatives into sustained profitability and positive cash flow before considering a stronger position.

Keywords

Lifecore Biomedical, CDMO, Hyaluronic Acid, Sterile Injectables, Pharmaceutical Manufacturing, Medical Device, SEC Filing, 10-K, Financial Results, Corporate Governance, Risk Factors, Debt, Preferred Stock, Nasdaq Compliance, Internal Controls, Litigation, Capital Raise